Finkelstein Thompson LLP is investigating potential claims on behalf of shareholders of QuadraMed Corp. ("QuadraMed" or the "Company") (NasdaqGM:QDHC) arising from the Company's announcement of its intent to be acquired by Francisco Partners in a going private transaction.

On December 8, 2009, QuadraMed announced its plan to be acquired by the private equity firm Francisco Partners. Under the terms of the merger agreement, QuadraMed shareholders will receive $8.50 in cash for every share of QuadraMed common stock they own. Just two days after the announcement of the merger, QuadraMed reported that the Department of Veterans Affairs renewed a contract with the Company worth a reported $24 million.

The investigation is focused on the potential unfairness of the consideration to be paid to QuadraMed shareholders as well as the potential unfairness of the process by which the QuadraMed Board of Directors is addressing the transaction.

If you are interested in discussing your rights as a QuadraMed shareholder, or have information relating to this investigation, please contact Finkelstein Thompson's Washington, DC offices at (877) 337-1050 or by email at This email address is being protected from spam bots, you need Javascript enabled to view it .